Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) has provided an announcement.
Nanjing Leads Biolabs Co., Ltd. has scheduled a board meeting for 27 March 2026 to review and approve the annual results of the company and its subsidiaries for the year ended 31 December 2025, and to authorize their release to the market. The board will also consider whether to recommend a dividend, a decision that could inform investors about management’s assessment of the company’s financial strength and capital‑allocation priorities.
The announcement, signed by chairman and chief executive officer Dr. Kang Xiaoqiang, underscores the company’s adherence to Hong Kong listing requirements on timely disclosure of financial information. By flagging the potential dividend decision in advance, Nanjing Leads Biolabs signals to shareholders that the upcoming results meeting may have direct implications for their returns and for the firm’s stance on shareholder distributions.
The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.
More about Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a PRC‑incorporated biopharmaceutical company listed in Hong Kong under stock code 9887. The firm is governed by a board comprising executive, non‑executive and independent non‑executive directors, reflecting a standard listed‑company governance structure aimed at supporting its life‑sciences operations and capital‑market activities.
Average Trading Volume: 596,122
Technical Sentiment Signal: Hold
Current Market Cap: HK$12.66B
See more data about 9887 stock on TipRanks’ Stock Analysis page.